S&CO Inc. lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 74.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,050 shares of the biopharmaceutical company's stock after buying an additional 4,300 shares during the quarter. S&CO Inc.'s holdings in Alnylam Pharmaceuticals were worth $2,713,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Capital World Investors raised its stake in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after buying an additional 92,101 shares during the last quarter. Capital Research Global Investors raised its stake in Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after purchasing an additional 1,724,610 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after purchasing an additional 1,245,195 shares during the last quarter. Geode Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 2,206,800 shares of the biopharmaceutical company's stock valued at $518,367,000 after purchasing an additional 59,597 shares during the last quarter. Finally, Groupama Asset Managment raised its stake in Alnylam Pharmaceuticals by 0.5% in the 4th quarter. Groupama Asset Managment now owns 1,528,450 shares of the biopharmaceutical company's stock valued at $359,660,000 after purchasing an additional 7,065 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.
Insiders Place Their Bets
In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the company's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the transaction, the chief executive officer owned 48,948 shares in the company, valued at $14,899,281.72. This represents a 39.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on ALNY shares. UBS Group boosted their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a research note on Friday. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a report on Friday. Citigroup lifted their price target on Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the company a "buy" rating in a report on Friday, July 11th. Morgan Stanley lifted their price target on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a report on Friday. Finally, BMO Capital Markets lifted their price target on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a report on Tuesday, June 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-three have assigned a buy rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $387.63.
Check Out Our Latest Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Stock Up 2.4%
NASDAQ ALNY traded up $9.56 on Friday, reaching $401.80. The company had a trading volume of 1,756,625 shares, compared to its average volume of 924,546. The firm has a market capitalization of $52.39 billion, a PE ratio of -192.25 and a beta of 0.23. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $402.43. The firm has a 50-day moving average of $316.00 and a 200-day moving average of $277.50. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm's revenue was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.16) EPS. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
(
Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Further Reading
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
